CA3042459A1 - Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies - Google Patents

Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies Download PDF

Info

Publication number
CA3042459A1
CA3042459A1 CA3042459A CA3042459A CA3042459A1 CA 3042459 A1 CA3042459 A1 CA 3042459A1 CA 3042459 A CA3042459 A CA 3042459A CA 3042459 A CA3042459 A CA 3042459A CA 3042459 A1 CA3042459 A1 CA 3042459A1
Authority
CA
Canada
Prior art keywords
cardiac
irregularity
alteration
condition resulting
lipid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA3042459A
Other languages
English (en)
Other versions
CA3042459C (fr
Inventor
Lawrence Helson
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/347,381 external-priority patent/US10117881B2/en
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of CA3042459A1 publication Critical patent/CA3042459A1/fr
Application granted granted Critical
Publication of CA3042459C publication Critical patent/CA3042459C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne des compositions et des méthodes utiles pour prévenir un ou plusieurs états ou canalopathies cardiaques résultant d'irrégularités ou modifications de types cardiaques provoquées par un agent actif ou un médicament chez un sujet humain ou animal, comprenant: une quantité d'un composé de lysophosphatidyle conçu pour une administration par voie orale efficace pour réduire ou prévenir un ou plusieurs états ou canalopathies cardiaques résultant d'irrégularités ou modifications de types cardiaques provoquées par l'agent actif ou le médicament.
CA3042459A 2016-11-09 2017-11-09 Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies Active CA3042459C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/347,381 2016-11-09
US15/347,381 US10117881B2 (en) 2011-06-03 2016-11-09 Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
PCT/US2017/060936 WO2018089687A1 (fr) 2016-11-09 2017-11-09 Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des médicaments provoquant des canalopathies

Publications (2)

Publication Number Publication Date
CA3042459A1 true CA3042459A1 (fr) 2018-05-17
CA3042459C CA3042459C (fr) 2022-08-16

Family

ID=62109333

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3042459A Active CA3042459C (fr) 2016-11-09 2017-11-09 Effet protecteur de dmpc, dmpg, dmpc/dmpg, lysopg et lysopc contre des medicaments provoquant des canalopathies

Country Status (8)

Country Link
EP (1) EP3538106A4 (fr)
JP (1) JP2019533692A (fr)
KR (3) KR20190067918A (fr)
CN (1) CN110167562A (fr)
AU (1) AU2017357916B2 (fr)
CA (1) CA3042459C (fr)
MX (1) MX2019005141A (fr)
WO (1) WO2018089687A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018209164B2 (en) 2017-01-17 2021-11-04 Heparegenix Gmbh Protein kinase inhibitors for promoting liver regeneration or reducing or preventing hepatocyte death
US10835529B2 (en) 2017-05-16 2020-11-17 Bow River LLC Methods of treatment with CYP3A4 substrate drugs
US10857144B2 (en) 2017-05-16 2020-12-08 Bow River LLC Methods of treatment
EP3426250B1 (fr) 2017-05-16 2022-03-23 Bow River LLC Traiter un patient avec un substrat du cyp3a4 contre-indiqué pour l'administration concomitante avec un inhibiteur fort du cyp3a4
US20220143011A1 (en) 2017-05-16 2022-05-12 Bow River LLC Methods of treatment with cyp3a4 substrate drugs
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
JP2024039728A (ja) * 2022-09-12 2024-03-25 賢一郎 蓮見 抗腫瘍免疫応答増強剤

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4812312A (en) * 1987-03-03 1989-03-14 Board Of Regents Of The University Of Texas System Liposome-incorporated nystatin
JPH10279487A (ja) * 1997-04-01 1998-10-20 Nippon Shokuhin Kako Co Ltd 脂質代謝改善剤
US20100068251A1 (en) * 2006-10-10 2010-03-18 Jina Pharmaceuticals, Inc. Aqueous Systems For The Preparation Of Lipid Based Pharmaceutical Compounds; Compositions, Methods, And Uses Thereof
US9447027B2 (en) * 2010-10-22 2016-09-20 The General Hospital Corporation Treating long QT syndrome
US10532045B2 (en) * 2013-12-18 2020-01-14 Signpath Pharma, Inc. Liposomal mitigation of drug-induced inhibition of the cardiac IKr channel
US10117881B2 (en) * 2011-06-03 2018-11-06 Signpath Pharma, Inc. Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
CA2836904C (fr) * 2011-06-03 2019-09-24 Signpath Pharma Inc. Attenuation liposomale du syndrome du qt long induit par un medicament et du courant de potassium a redressement retarde
JP2017516813A (ja) * 2014-06-03 2017-06-22 サインパス ファルマ, インク.Signpath Pharma, Inc. チャネル病を引き起こす薬物に対するｄｍｐｃ、ｄｍｐｇ、ｄｍｐｃ／ｄｍｐｇ、ｅｇｐｇ、ｌｙｓｏｐｇ及びｌｙｓｏｐｃの防御効果

Also Published As

Publication number Publication date
AU2017357916A1 (en) 2019-05-30
EP3538106A4 (fr) 2021-03-24
CN110167562A (zh) 2019-08-23
AU2017357916B2 (en) 2020-11-26
WO2018089687A1 (fr) 2018-05-17
KR20190067918A (ko) 2019-06-17
KR20200108371A (ko) 2020-09-17
MX2019005141A (es) 2019-09-26
CA3042459C (fr) 2022-08-16
JP2019533692A (ja) 2019-11-21
EP3538106A1 (fr) 2019-09-18
KR20230110823A (ko) 2023-07-25

Similar Documents

Publication Publication Date Title
US10117881B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, LYSOPG and LYSOPC against drugs that cause channelopathies
AU2017357916B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, LysoPG and LysoPC against drugs that cause channelopathies
US10357458B2 (en) Liposomal mitigation of drug-induced long QT syndrome and potassium delayed-rectifier current
AU2015269699B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, EGPG, LysoPG and LysoPC against drugs that cause channelopathies
EP3082768B1 (fr) Atténuation liposomale de l'inhibition induite par médicament du canal ikr cardiaque
US10449193B2 (en) Protective effect of DMPC, DMPG, DMPC/DMPG, lysoPG and lysoPC against drugs that cause channelopathies
TWI731336B (zh) 新穎脂質
US20230042703A1 (en) Cardioprotective Lipid and Method of Use
EP3326616B1 (fr) Atténuation liposomale du syndrome du qt long induit par un médicament et du courant de potassium à redressement retardé
WO2024064536A1 (fr) Lipide cardioprotecteur et procédé d'utilisation
EP4234037A2 (fr) Compositions liquides pour l'usage péroral comprennant dérivés de phosphatidylglycerol et excipients thixotropiques pour le traitement de canalopaties cardiaques causeés par agents pharmacologiques

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190430

EEER Examination request

Effective date: 20190430